Thomas J. Vasicek, Ph.D.
Co-founder & CEO, Gila Therapeutics
Dr. Vasicek previously led development of gut hormone therapies for obesity and clinical trials of pump-delivered interferon alpha for hepatitis-C at Medtronic. He has extensive startup experience –Millennium, LabSeek, Lynx, HTG and others – and he has established new ventures within Corning, Medtronic and Roche. In the 1990s he began working with obesity genes; then in the 2000s at Medtronic, he used insulin pumps to deliver satiety protein to human subjects with obesity. Dr. Vasicek has 26 publications and four patent applications.